The competitive landscape for regenerative medicine continues to evolve. As private sector investment in active players continues, efforts by governments in the US and EU are helping to advance the field, including the recent passage of the 21st Century Cures Act in the US, providing a special status pathway for regenerative medicine advanced therapies.
Over the past five years, deal-making has occurred at a rapid pace, and regenerative medicine-focused biotech companies have drawn top dollar in both partnering and mergers and acquisitions.
The regenerative medicine market is undergoing many changes, and involves several modalities, from cell and gene therapies, to gene editing technologies, and tissue regeneration products.
Devices, including tissue engineering products, currently dominate the marketed regenerative medicine portfolio, but this is expected to change as the pipeline for pharmaceuticals, namely cell and gene therapies, numbers in the thousands and includes a strong Phase II program as well as many novel candidates awaiting approval.
For the purposes of this report, the regenerative medicine market is broadly divided into device and therapy categories in the Key Company Players in Regenerative Medicine, Regenerative Medicine Approved Product Trends, and Regenerative Medicine Pipeline Trends chapters, followed by further market segmentation.
The regenerative medicine device category includes biologic bone regenerative and repair devices, biologic soft tissue regeneration and repair devices, musculoskeletal scaffolds, and other tissue engineering products. The regenerative medicine therapy category covers cell therapies, gene therapies, and gene editing.
Our reports have been used by over 10K customers, including:
700 pages •
By Kelly Scientific Publications
• Jan 2019
This report provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of therapies that are in clinical trials. Kelly Scientific analysis indicates that the global regenerative medicine market was...
Adenoviridae Infections Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Adenoviridae Infections Global Clinical Trials Review, H2, 2018" provides an overview of Adenoviridae Infections clinical trials scenario.This report provides top line data relating to the...
167 pages •
By Global Industry Analysts
• Jan 2019
This report analyzes the worldwide markets for Mesenchymal Stem Cells in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic...
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 22.214.171.124) - Pipeline Review, H2 2018 Summary Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 126.96.36.199)...
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.